1-4 of 4
Caroline Lehmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax plus obinutuzumab improves quality of life in treatment-naive CLL: Prospective real-world insights from the verve study

Free
Ingo Schwaner, Holger Hebart, Thomas Wolff, Caroline Lehmann, Eva Runkel, Burkhard Schmidt, Petra Pichler, Davide Rossi
Journal: Blood
Blood (2025) 146 (Supplement 1): 2117.
https://doi.org/10.1182/blood-2025-2117
Published: 2025
Journal Articles

Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting

Free
Ilaria Romano, Alessio Bruscaggin, Georg Stussi, Simone Bocchetta, Katia Pini, Gabriela Forestieri, Maria Pirosa, Mathias Oertli, Xenia Schmidt, Caroline Lehmann, Thomas Noesslinger, Ingo Schwaner, Monica Gallucci, Heidi Simmons, Davide Rossi, Adalgisa Condoluci
Journal: Blood
Blood (2025) 146 (Supplement 1): 3901.
https://doi.org/10.1182/blood-2025-3901
Published: 2025
Journal Articles

Clinical Outcomes of CLL Patients Treated with Venetoclax Under Real-World Conditions in Austria, Germany, and Switzerland after Treatment with Ibrutinib

Free
Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi
Journal: Blood
Blood (2024) 144 (Supplement 1): 6788.
https://doi.org/10.1182/blood-2024-200644
Published: 2024
Journal Articles

Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland

Free
Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi
Journal: Blood
Blood (2023) 142 (Supplement 1): 4654.
https://doi.org/10.1182/blood-2023-174387
Published: 2023